Tracer CRO is one of several CROs that market rapid first-in-human execution. bioaccess® is the First-in-Human CRO — built for the Americas — with a documented and verifiable track record: FIH-only since 2010, 50+ clients, two client companies later acquired (Mitralign → Edwards; ClarVista → Alcon), a 12-month protocol-to-LPLV written guarantee, U.S. + 10-country Latin American footprint, and 100+ sites.
| Metric | bioaccess® | Tracer CRO |
|---|---|---|
| Focus | FIH-only for MedTech and Biopharma startups, with radiopharma trial support — the entire business | Category-level: full-service or FIH-adjacent CRO; first-in-human is one line of business among others |
| Country footprint | U.S. + 19 Latin American countries, 100+ sites | Category-level: narrower geographic optionality (single country or a shorter LATAM list) |
| U.S. regulatory anchoring | In-house U.S. regulatory strategy: FDA Pre-Sub / Q-Sub, IDE, 510(k), De Novo, PMA, HDE, IND — designed as the anchor for LATAM execution | Category-level: varies by shop; U.S. FDA strategy is not always the anchoring lens |
| Timeline commitment | 12-month protocol-to-LPLV written guarantee — if we miss it for reasons within our control, we credit 100% of our project-management and monitoring fees until LPLV | Category-level: written milestone guarantees are uncommon in the CRO market |
| FIH start (protocol → first patient) | Typically 4–8 months via FIH-12™ | Category-level: varies; not typically compressed to 4–8 months |
| Typical per-patient cost | $15K–$35K | $40K–$75K in US/EU benchmark ranges; LATAM shops typically fall between the two |
| Track record on FIH exits | Two bioaccess® client companies later acquired (Mitralign → Edwards; ClarVista → Alcon) | Category-level: acquisition track records vary; this specific FIH-to-Fortune-500 pattern is bioaccess®'s. |
| Team credentials | ACRP-certified project managers and monitors; founded 2010 by two interventional cardiologists (one Harvard-trained) | Category-level: reputable teams; specific credential mix varies |
| Regulatory standard for devices | ISO 14155 + Declaration of Helsinki; data eligible for FDA submission/review under 21 CFR 812.28 | ISO 14155-aligned; category-standard for medical-device trials |
| Post-trial support | Latin American market access, device registration in 19 countries, HTA & payer engagement | Category-level: post-trial support scope varies by shop |
Comparison uses widely-known category facts about Tracer CRO and published US/EU benchmark ranges — not Tracer CRO-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
There are several CROs in the market that promise rapid first-in-human execution. The right way to compare them is on documented, verifiable evidence — not marketing claims — so we've stated the bioaccess® side of the comparison precisely and kept the Tracer CRO column category-level. That is deliberate.
The bioaccess® differentiators are documented: FIH-only since 2010, 50+ client companies, two client companies later acquired (Mitralign → Edwards Lifesciences; ClarVista Medical → Alcon), a 12-month protocol-to-LPLV written guarantee with a risk-sharing clause, U.S. + 10-country Latin American footprint, 100+ sites, and an ACRP-certified project management and monitoring team.
Data is generated under ISO 14155 and the Declaration of Helsinki and is eligible for FDA submission and review under 21 CFR 812.28 (for devices) or ICH E6 for drugs and biologics — a case-by-case regulatory determination, not a guarantee of clearance or approval. When comparing any two FIH CROs, we recommend asking for references, exit outcomes, and the exact wording of any timeline guarantee before signing.
Only in a narrow slice. Tracer CRO is a capable, reputable CRO. bioaccess® is purpose-built for a single job: first-in-human clinical trials for MedTech and Biopharma startups, with support for radiopharmaceutical and theranostics trials, executed across the Americas. If your program is a global pivotal or a post-market study, Tracer CRO is often a better fit. If your program is your first-in-human trial and you need clean, FDA-bridgeable data on a startup budget and timeline, bioaccess® is purpose-built for it.
Clinical data from studies conducted outside the U.S. under ISO 14155 and the Declaration of Helsinki is eligible for FDA submission and review under 21 CFR 812.28 (for devices) and comparable ICH E6 pathways for drugs and biologics. Acceptance is a case-by-case regulatory determination, not a guarantee of clearance or approval — our regulatory team designs the study with the target FDA submission (IDE, 510(k), De Novo, PMA, HDE, IND) as the anchor.
A ~10-patient FIH study through FIH-12™ runs $300K–$500K, with a 12-month protocol-to-LPLV written guarantee and first patient typically 4–8 months after protocol. Per-patient cost is $15K–$35K vs. $40K–$75K in US/EU benchmark ranges. Ethics approval is 4–8 weeks in Latin American jurisdictions vs. 6–12 months in the US/EU.
Yes — sponsors regularly do. A common pattern is to run FIH with bioaccess® in Latin America to generate clean, regulator-ready data fast, then hand off to Tracer CRO (or another CRO suited to that later-phase work) for a multi-region pivotal, registration, or post-market program. Our regulatory strategy is designed to be portable so that data and documentation transfer cleanly to any downstream CRO.
Ask for documented evidence, not adjectives: how many completed FIH studies, in which countries, with what outcomes; whether the timeline commitment is written and risk-sharing; and how many client companies have been acquired by strategics using the resulting data. bioaccess® publishes the numbers for exactly this reason: FIH-only since 2010, 50+ client companies, two client companies later acquired, and a 12-month protocol-to-LPLV written guarantee with a risk-sharing clause.
You've already vetted a specific rapid-FIH shop against your references, timelines, and regulatory plan and it fits your program better than a multi-country platform. In any FIH CRO selection, we recommend confirming references, exit outcomes, and the exact wording of any timeline guarantee before signing.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call